Roche Set To Buy United States Biotech Firm InterMune For $8.3 Billion

By: | August 25th, 2014

There is yet another multibillion-dollar deal in a consolidating pharmaceutical sector, as Roche Holding AG has agreed to buy United States biotech company InterMune Inc for $8.3 billion in cash.

Announced this past Sunday, Swiss company Roche will pay $74.00 a share for InterMune, a premium of 38 percent to the closing price on Aug. 22.

It will be interesting to see how this move pans out for Roche moving forward.

Technology, engineering, and design enthusiast.

Google+ 

More articles from Industry Tap...